VGT-309

MINNEAPOLIS, Minn., January 28, 2024 – Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS24). The data demonstrate that VGT-309, the company’s investigational tumor-targeted fluorescent imaging agent, visualizes primary and metastatic tumor tissue in the lung during surgery. The findings reinforce results from earlier clinical trials of VGT-309 which suggest the agent may help surgeons see difficult-to-find and previously undetected tumors in real time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted lung cancer surgery. “The data presented today at STS 2024 suggest that VGT-309 could help support more confident and reliable removal of a wide breadth of cancers in the lung that would otherwise be missed during minimally invasive and robotic surgery,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “We look forward to the results from our ongoing, Phase 2 multi-center VISUALIZE study, which will provide further insight regarding the potential promising impact of VGT-309 for both cancer patients and surgeons.” The VGT-309 Phase 2* efficacy study evaluated the frequency that intraoperative molecular imaging (IMI) improved surgical outcomes in 40 individuals with suspected or proven cancer in the lung who were eligible for surgery. The primary efficacy endpoint was the proportion of patients with at least one clinically significant event. Clinically significant events were defined as localization of lesions not found by standard surgical techniques, identification of synchronous and occult cancers, and inadequate surgical margin. Each patient in the study received VGT-309 preoperatively through intravenous infusion. Following an attempt to localize tumors using standard surgical techniques, investigators used a commercially available near infrared (NIR) endoscope to assess the presence of tumor tissue, which was then confirmed by pathology. Of the 40 participants administered VGT-309 who underwent the standard-of-care surgical resection for suspected lung cancer, 17 (42.5%) had at least one clinically significant event. VGT-309 with NIR fluorescence imaging visualized a range of primary and metastatic tumor types intraoperatively, including adenocarcinoma in situ, invasive adenocarcinoma, lymphoma, colorectal cancer, neuroendocrine tumors, sarcomas, and squamous cell carcinoma. VGT-309 was safe and well tolerated in this study, with no infusion reactions and no drug-related serious adverse events. “Minimally invasive surgery has become standard of care for many cancer surgeries, but surgeons’ ability to see and remove all tumor tissue during these procedures is often hindered by poor visualization,” said Sunil Singhal, M.D., lead investigator and chief of the division of thoracic surgery in the Perelman School of Medicine at University of Pennsylvania. “The data from the VGT-309 Phase 2 efficacy study are encouraging, reinforcing the agent’s potential to help fill this critical gap.” *This clinical trial ( ClinicalTrials.gov Identifier: NCT05400226) was supported by the National Cancer Institute of the National Institutes of Health under award number R44CA277890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About VGT-309 VGT-309 is a tumor-targeted imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive surgery (MIS), and robotic-assisted surgical procedures. VGT-309 is delivered to patients via a short infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, provides distinct clinical advantages and positions VGT-309 as an ideal tumor imaging agent. VGT-309’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is the preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience, Inc. Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating VGT-309 for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN. Vergent Bioscience Australia Pty Ltd is a wholly owned subsidiary of Vergent Bioscience. Source: Vergent Bioscience, Inc. Posted: January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

STS 2024 session will highlight potential of tumor-targeted fluorescent imaging agent to enhance minimally invasive surgery by improving the visualization of cancer in the lung MINNEAPOLIS--(BUSINESS WIRE)-- Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that new results from the Phase 2 clinical program evaluating the company’s investigational agent VGT-309 will be presented at STS 2024, the 60th Annual Meeting of The Society of Thoracic Surgeons, taking place January 27-29, 2024, in San Antonio, Texas. “Our VGT-309 clinical program has produced an encouraging body of evidence demonstrating the potential of our highly differentiated imaging agent to improve standard of care surgery for patients with cancer in the lung,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “We look forward to sharing the latest data from this program with the surgical and medical research communities at STS 2024.” The Phase 2 single-center clinical efficacy study of VGT-309 was led by Sunil Singhal, M.D., William Maul Measey Professor in Surgical Research at University of Pennsylvania Perelman School of Medicine. The study involved 40 participants who underwent surgical resection for known or suspected cancer in the lung.* Findings to be presented at STS 2024 build upon results from earlier Phase 1 safety and Phase 2 dose-ranging clinical trials of VGT-309 demonstrating the agent’s potential to help surgeons see difficult-to-find and previously undetected tumors in real time to improve surgical outcomes. Following are details about the VGT-309 presentation at STS 2024: Title: A Phase 2 Clinical Trial of VGT-309, a Quenched Activity-Based Probe for Intraoperative Molecular Imaging of Pulmonary Malignancies Presenter: Patrick Bou-Samra, M.D., Division of Surgery, University of Pennsylvania, Perelman School of Medicine Session: General Thoracic. At the Cutting Edge: Emerging Technologies in Lung Cancer Date/Time: Sunday, January 28, 2024, 2:40 p.m. – 2:52 p.m. CT *This clinical trial (ClinicalTrials.gov Identifier: NCT05400226) was supported by the National Cancer Institute of the National Institutes of Health under award number R44CA277890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About VGT-309 VGT-309 is a tumor-targeted imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive surgery (MIS), and robotic-assisted surgical procedures. VGT-309 is delivered to patients via a short infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, provides distinct clinical advantages and positions VGT-309 as an ideal tumor imaging agent. VGT-309’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is the preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating VGT-309 for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN. Vergent Bioscience Australia Pty Ltd is a wholly owned subsidiary of Vergent Bioscience. For more information, visit vergentbio.com